Abstract
In the present study, we aimed to evaluate the effectiveness of second-line gemcitabine-based chemotherapy regimens on overall survival (OS) in malignant pleural mesothelioma (MPM) patients receiving first-line pemetrexed-based regimens. A total of 73 patients with MPM from Akdeniz University, Acibadem Kayseri Hospital, Kayseri Training and Research Hospital, and Erciyes University were analyzed and evaluated retrospectively as two groups: second-line gemcitabine-based chemotherapy and no second-line chemotherapy. The median OS of patients who received second-line gemcitabine-based chemotherapy was 11.3 (5.1–17.5) months, while it was 9.9 (2.1–17.7) months in the patients who did not receive chemotherapy in the second-line setting (p = 0.056). When we evaluated the survival rate at the 6th, 12th, 18th, 24th, and 36th month, the OS rate of the 36th month was significantly higher in patients who received gemcitabine-based second-line chemotherapy (p = 0.041). When evaluating the OS from diagnosis to death, the median OS values were 20.8 (17.5–24.1) months for first-line pemetrexed-based regimens then second-line gemcitabine alone and 13.1 (9.0–17.1) months supportive care after first-line pemetrexed-based regimens (p = 0.005). According to our results, we may consider gemcitabine-based regimens as second-line chemotherapy after treatment with pemetrexed plus platinum in patients with MPM.
Similar content being viewed by others
References
Mutlu H, Buyukcelik A, Karaca H, Aksahin A, Berk V, Aslan T, Erden A, Akca Z, Ozkan M. Secondline chemotherapy versus best supportive care in patient with malignant pleural mesothelioma: a retrospective study. Asian Pac J Cancer Prev. 2013;14:3887–9.
Seer.cancer.gov/csr/2004_2008/results.
Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–44.
van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G. European Organisation for Research and Treatment of Cancer Lung Cancer Group; National Cancer Institute of Canada Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23:6881–9.
Mott FE. Mesothelioma: a review. Ochsner J. 2012;12:70–9.
Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 2008;26:1698–704.
Portalone L, Antilli A, Nunziati F, Crispino C, de Marinis F, Friggeri L, Lombardi A, Lorusso V, Pronzato P, Sambiasi D, et al. Associazione Italiana pneumologi ospedalieri thoracic oncology study group. Epirubicin and gemcitabine as first-line treatment in malignant pleural mesothelioma. Tumori. 2005;91:15–8.
Utkan G, Büyükçelik A, Yalçin B, Akbulut H, Demirkazik A, Dinçol D, Onur H, Gören D, Mousa U, Senler FC, et al. Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma. Lung Cancer. 2006;53:367–74.
Kalmadi SR, Rankin C, Kraut MJ, Jacobs AD, Petrylak DP, Adelstein DJ, Keohan ML, Taub RN, Borden EC. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer. 2008;60:259–63.
Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, Mitchell P, Musk AW, Robinson BW. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer. 2002;87:491.
Castagneto B, Zai S, Dongiovanni D, Muzio A, Bretti S, Numico G, Botta M, Sinaccio G. Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol. 2005;28:223.
Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Jänne PA, Quinn DI, Koczywas MN, Brahmer JR, et al. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012;30:2509–15.
Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
Toyokawa G, Takenoyama M, Hirai F, Toyozawa R, Inamasu E, Kojo M, Morodomi Y, Shiraishi Y, Takenaka T, Yamaguchi M, et al. Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy. Int J Clin Oncol. 2013. doi:10.1007/s10147-013-0619-5.
Margery J, Rivière F, Planchard D, Le Floch H, Ferrand FR, Mairovitz A, Besse B, Vaylet F, Ruffié P. Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005–2006). Rev Pneumol Clin. 2010;66:255–9.
Zucali PA, Ceresoli GL, Garassino I, De Vincenzo F, Cavina R, Campagnoli E, Cappuzzo F, Salamina S, Soto Parra HJ, Santoro A. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer. 2008;112:1555–61.
Tourkantonis I, Makrilia N, Ralli M, Alamara C, Nikolaidis I, Tsimpoukis S, Charpidou A, Kotanidou A, Syrigos K. Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural mesothelioma: a single institution study. Am J Clin Oncol. 2011;34:38–42.
Xanthopoulos A, Bauer TT, Blum TG, Kollmeier J, Schönfeld N, Serke M. Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study. J Occup Med Toxicol. 2008;18(3):34.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mutlu, H., Gündüz, Ş., Karaca, H. et al. Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study. Med Oncol 31, 74 (2014). https://doi.org/10.1007/s12032-014-0074-9
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12032-014-0074-9